Showing 511-520 of 3714 results for "".
- Lebrikizumab Linked with Improvement in Patients with AD and Skin of Colorhttps://practicaldermatology.com/news/lebrikizumab-linked-with-improvement-in-patients-with-atopic-dermatitis-and-skin-of-color/2462431/New first-of-its-kind research presented at the American Academy of Dermatology 2024 Annual Meeting suggests that lebrikizumab showed efficacy in patients with skin of color who had atopic dermatitis (AD). “People with skin of color are disproportionately affected by AD, often experiencing more se…
- Galderma to Showcase Latest Updates From Its Dermatology Portfolio at the 2024 AAD Annual Meetinghttps://practicaldermatology.com/news/galderma-to-showcase-latest-updates-from-its-dermatology-portfolio-at-the-2024-american-academy-of-dermatology-annual-meeting-1/2462259/Galderma will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) annual meeting from March 8-12, 2024, highlighting its dermatology portfolio. Galderma’s presence includes two late-breaking presentations on its first-in-class, investigational mono…
- EULAR News: Acelyrin's IL-17A Blocker Performs Well in PsAhttps://practicaldermatology.com/news/eular-news-acelyrins-il-17a-blocker-performs-well-in-psa/2461657/ACELYRIN, INC.’s IL-17A blocker izokibep demonstrated higher levels of response across psoriatic arthritis disease manifestations, according to 46-week data from a global Phase 2 trial of izokibep in psoriatic arthritis (PsA). Izokibep is a small protein therapeutic designed to inhibit interleuk…
- Experts React to Approval of Pfizer’s CIBINQO for Teens With Refractory ADhttps://practicaldermatology.com/news/fda-oks-pfizers-cibinqo-for-teens-with-refractory-ad/2461560/The US FDA has approved a supplemental New Drug Application (sNDA) for CIBINQO (abrocitinib, Pfizer). This move expands the drug's indication to include adolescents (12 to < 18 years) with refractory, moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with other sy…
- FDA Clears Soligenix's Synthetic Hypericin for Phase 2 Clinical Trial in Psoriasishttps://practicaldermatology.com/news/fda-clears-soligenixs-synthetic-hypericin-for-phase-2-clinical-trial-in-psoriasis/2461250/The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s Investigational New Drug (IND) application for a Phase 2a clinical trial of topically-applied SGX302 (synthetic hypericin). Patient enrollment is slated to begin in the fourth quarter of 2022. "During the last year, we have made …
- Soligenix to Advance Synthetic Hypericin Development in Psoriasishttps://practicaldermatology.com/news/soligenix-to-advance-synthetic-hypericin-development-in-psoriasis/2460917/Soligenix, Inc. will be expanding synthetic hypericin development under the research name SGX302 into psoriasis. The company made this move after the validation of synthetic hypericin's biologic activity in the positive pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study…
- Chicago Dermatologist Dr. Amy S. Paller Wins American Skin Association’s David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/chicago-dermatologist-dr-amy-s-paller-wins-american-skin-associations-david-martin-carter-mentor-award/2460802/Amy S. Paller, MD of the Feinberg School of Medicine at Northwestern University in Chicago received the American Skin Association's David Martin Carter Mentor Award. For more than three decades, ASA's David Martin Carter Mentor Award has honored members of the dermatology community who embody the …
- Etrasimod Performs Well in Phase Phase 2b Trial of Adult Atopic Dermatitishttps://practicaldermatology.com/news/etrasimod-performs-well-in-phase-phase-2b-trial-of-adult-atopic-dermatitis/2460761/Arena Pharmaceuticals, Inc.’s Etrasimod demonstrated statistical significance in both clinician and patient reported outcomes in atopic dermatitis, according to research presented at the American Academy of Dermatology VMX Experience. Etrasimod is an investigational, highly selective, once-daily, …
- Survey: Parents Extremely Worried About the Physical and Emotional Toll that Severe Acne Takes on Teenshttps://practicaldermatology.com/news/survey-parents-extremely-worried-about-the-physical-and-emotional-toll-that-severe-acne-takes-on-teens/2460734/Parents are very worried about the effects of severe acne on their teens, according to a new survey sponsored by Sun Pharma, in collaboration with the American Acne and Rosacea Society (AARS). The survey, which polled 250 parents of teenagers with severe nodular or cystic acne, showed that the vas…
- Telemedicine Slashes Dermatology Consult Time from 84 Days to 5 Hourshttps://practicaldermatology.com/news/telemedicine-slashes-dermatology-consult-time-from-84-days-to-5-hours/2460609/When patients’ primary care doctors were able to photograph areas of concern and share them with dermatologists, the response time for a consultation dropped from almost 84 days to under five hours, finds a new study from researchers in the Perelman School of Medicine at the University of Pennsylva…